Evidence map›Paper›PMID 40593464›Full record

ArticleLight, science & applications2025

Near-infrared light activatable chemically induced CRISPR system.

Lei Zhang, Xuejun Zhang, Le Qiu, Song Mao, Jia Sheng, Liming Chen, Umar Khan, Paul K Upputuri, Yuri N Zakharov, Mark F Coughlan and 1 more

Abstract read
In one paragraph

Article in Light, science & applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Near infrared light controlled gene editing.Light, science & applications · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lei Zhang *Center for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA. lzhang11@bidmc.harvard.edu.
Xuejun Zhang *Center for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.
Le Qiu *Center for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5392-2848
Song MaoThe RNA Institute, Department of Chemistry, University at Albany, Albany, NY, USA.
Jia ShengThe RNA Institute, Department of Chemistry, University at Albany, Albany, NY, USA. jsheng@albany.edu.
Liming ChenCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.
Umar KhanCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.
Paul K UpputuriCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.
Yuri N ZakharovCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1260-7080
Mark F CoughlanCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA.ORCID http://orcid.org/0000-0001-7421-507X
Lev T PerelmanCenter for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, MA, USA. ltperel@bidmc.harvard.edu.

Funding

Endoscopic Fine-Needle Polarized Scanning Spectroscopy for Pancreatic Cystic Lesions DiagnosisR01EB025173 · NIBIB · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Lev T Perelman · 2017 to 2026
$4.7M
Spectro-Holographic Instrument for Dynamic Sensing of Cancer ProgressionR01CA228029 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PERELMAN, LEV T · 2018 to 2023
$3.4M
Multispectral imaging of bile duct epithelial morphology for early detection of malignancyR01CA293050 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Lev T Perelman · 2024 to 2026
$2.1M
A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer’s diseaseR21AG085089 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Mark Coughlan · 2024 to 2026
$668k
National Science Foundation (NSF) CBET 1948722National Science Foundation (NSF) CBET 2325317National Science Foundation (NSF) EFRI 1830878NCI NIH HHS R01 CA228029NCI NIH HHS R01 CA293050NIA NIH HHS R21 AG085089NIBIB NIH HHS R01 EB025173
6 · The paper itself

Abstract

The biggest challenge in using CRISPR technologies, which limits their widespread application in medicine, is off-target effects. These effects could, in principle, be minimized by ensuring that CRISPR is activated primarily in the targeted cells, thereby reducing the likelihood of unintended genetic modifications in non-target tissues. Therefore, the development of a light activatable CRISPR approach to dynamically control gene activation in both space and time would be highly beneficial. A drawback is that the overwhelming majority of recently introduced light activatable CRISPR systems require UV or blue light exposure, severely limiting the penetration depth of light in tissue at which CRISPR can be activated, and, in the case of UV light, raising safety concerns. A small number of systems that activate CRISPR using longer wavelengths are hindered by either slow light activation or issues related to toxicity and biocompatibility of the proposed techniques in humans. To address this, we developed a split-Cas9/dCas9 system in which activation is achieved through a near-infrared photocleavable dimerization complex. This photoactivation method can be safely used in humans in vivo, easily adapted to different split-Cas9/dCas9 systems, and enables rapid, spatially precise light activation across various cell types.

Identifiers

PMID40593464
PMCPMC12214668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.